---
title: "Lexaria Bioscience Corp. 2026: Revenue $0 EPS ($0.08) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292529067.md"
description: "Lexaria Bioscience Corp. reported Q2026 results with $0 revenue and a diluted loss per share of ($0.08), narrowing net loss to ($1.99M) from ($3.79M) prior year. Revenue declined due to a strategic shift from B2B clients to licensing and pharmaceutical partnerships. The company completed Phase 1b GLP-1-H24-4 clinical studies, advanced R&D across multiple programs, secured FDA clearance for an IND-based hypertension program, and raised approximately $6.5M to fund operations into fiscal 2027."
datetime: "2026-07-13T20:31:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292529067.md)
  - [en](https://longbridge.com/en/news/292529067.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292529067.md)
generator: "portal-rs"
---

# Lexaria Bioscience Corp. 2026: Revenue $0 EPS ($0.08) — 10-Q Summary

Lexaria Bioscience Corp. reported results for the 2026 quarter with revenue of $0 and a diluted loss per share of ($0.08); net loss narrowed to ($1.99M) from ($3.79M) a year earlier.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$0

$174K

(100%)

Net income²

($1.99M)

($3.79M)

47.4%

Diluted EPS³

($0.08)

($0.21)

61.9%

*¹ Reported as “Revenue”. ² Reported as “Net loss attributable to Lexaria shareholders”. ³ Reported as “diluted loss per share”.*

**Business Highlights**

-   Completed the Phase 1b GLP-1‑H24‑4 clinical study and reported favorable safety and tolerability versus Rybelsus®.
-   Advancing R&D across GLP-1, GIP, glucagon and CBD programs with multiple human and animal studies underway.
-   Extended a materials transfer agreement with PharmaCO and received FDA clearance to proceed on an IND-based hypertension program.
-   Revenue declined as the company shifted from prior B2B clients toward licensing and pharmaceutical development partnerships.
-   Raised approximately $6.5M in two registered offerings to fund clinical trials and R&D into fiscal 2027.

Original SEC Filing: Lexaria Bioscience Corp. \[ LEXX \] - 10-Q - Jul. 13, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [LEXX.US](https://longbridge.com/en/quote/LEXX.US.md)
- [LEXXW.US](https://longbridge.com/en/quote/LEXXW.US.md)

## Related News & Research

- [LEXX: Revenue fell and losses narrowed as the company pivots to pharma R&D, raising going concern risks](https://longbridge.com/en/news/292528352.md)
- [Nvidia’s CEO draws Pope Leo’s criticism as AI safety concerns surge 50%](https://longbridge.com/en/news/300379637.md)
- [Nvidia Just Put $150 Billion Behind Its Stock. Is It Cheap Enough?](https://longbridge.com/en/news/300454444.md)
- [LIVE MARKETS-Wall Street's AI math doesn't add up](https://longbridge.com/en/news/300462731.md)
- [Amazon Ads presenta Amazon Ads Agent, su nueva solución publicitaria unificada impulsada por IA agéntica](https://longbridge.com/en/news/300461896.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**